source
- Parker Institute CEO Karen Knudsen says cancer research faces translation challengesKaren Knudsen, who has a track record of reshaping medical organizations, is now leading the Parker Institute for Cancer Immunotherapy, a nonprofit that turned ten years old this year. In a recent…
- Aclaris Therapeutics’ bosakitug fails Phase 2 eczema trial, TSLP program droppedAclaris Therapeutics announced that its experimental antibody bosakitug (ATI-045) did not meet the primary endpoint in a Phase 2 study for moderate-to-severe atopic dermatitis. The double‑blind Ad…